Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis

Clinical Endocrinology

Volumn 53, Issue 5, 2000, Pages 587-593

  Diez, J J ^a   Iglesias, P ^a   Selgas, R ^a   Bajo, M A ^a   Aguilera, A ^a  

^a NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; PIRENZEPINE; PYRIDOSTIGMINE;

ARTICLE; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HUMAN; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; UREMIA;

ADULT; AREA UNDER CURVE; CHOLINESTERASE INHIBITORS; ERYTHROPOIETIN, RECOMBINANT; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PERITONEAL DIALYSIS; PIRENZEPINE; PYRIDOSTIGMINE BROMIDE; UREMIA;

EID: 0033739613     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2000.01128.x     Document Type: Article

References (36)

1. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women
2. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man
3. Increased growth hormone response to growth hormone releasing hormone induced by erythropoietin in uraemic patients
4. Somatostatinergic tone in children on chronic haemodialysis and after renal transplantation
5. Effect of agonists and antagonists of cholinergic neurotransmission on growth hormone release in the dog
6. Atropine blockade of growth hormone (GH)-releasing hormone-induced GH secretion in man is not exerted at pituitary level
7. Different effects of naloxone on the growth hormone response to melatonin and pyridostigmine in normal men
8. Physiological role of the opioid-cholinergic interaction in growth hormone neuroregulation: Effect of sex and food intake
9. Pyridostigmine does not reverse dexamethasone-induced growth hormone inhibition
10. Participation of cholinergic muscarinic receptors in glucagon and arginine mediated growth hormone secretion in man
11. Interaction of glucose and pyridostigmine on the secretion of growth hormone (GH) induced by GH-releasing hormone (GHRH)
12. Growth hormone neuroregulatiion and its alterations in disease states
13. Effects of cholinergic muscarinic blockade on growth hormone responses to growth hormone-releasing hormone in uraemic patients
14. Long-term effects of recombinant human erythropoietin therapy on growth hormone secretion in uremic patients undergoing peritoneal dialysis
15. Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release
16. Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease
17. Effects of cholinergic blockade on nocturnal thyrotropin and growth hormone (GH) secretion in type 1 diabetes mellitus: Further evidence supporting somatostatin's involvement in GH suppression
18. The role of the cholinergic pathway in growth hormone feedback
19. Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: Evidence for mediation by somatostatin
20. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose
21. Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus
22. Responses of insulin, glucagon and growth hormone to arginine inlusion in patients with chronic renal failure
23. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: Studies in normal and acromegalic subjects
24. Blockade of hp-GRF-40-induced GH release in normal men by a cholinergic muscarinic antagonist
25. Potentiation of cholinergic bone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone releasing factor in man
26. Aspects of the neuroendocrine control of somatotropic function in callorically restricted dogs and patients with eating disorders: Studies with cholinergic drugs
27. Cholinergic modulation of growth hormone-releasing hormone effects on growth hormone secretion in dementia
28. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone releasing hormone induced growth hormone secretion in man: Suggesting that glucose acts through hypothalamic release of somatostatin
29. Role of cholinergic muscarinic pathways on the free fatty acid inhibition of GH responses to GHRH in normal men
30. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects
31. Responses to growth hormone-releasing hormone in adult renal failure patients on hemodialysis
32. Abnormalities in the regulation of growth hormone in chronic renal failure
33. Anterior pituitary dysfunction in patients with chronic renal failure treated by hemodialysis or continuous ambulatory peritoneal dialysis
34. Growth hormone in obesity
35. Effect of pyridostigmine and pirenzepine on GH responses to GHRH in hyperthyroid patients
36. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: Studies with GH-releasing hormone, pyridostigmine, and arginine